Account
Watchlists
Bookmarks
Pricing
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2025
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Bearish
4
Neutral
9
Bullish
1
Bearish
29
Neutral
9
Bullish
8
Bearish
25
Neutral
0
Bullish
7
Market Cap
₹ 275 Cr
P/E
96.02
Zenotech Laboratories Limited specializes in manufacturing pharmaceutical specialty generic injectables. It serves therapeutic areas such as oncology and anesthesiology, providing critical care solutions.
The company has undergone multiple mergers, significantly enhancing its product portfolio, particularly in oncology, with 15 generic chemical oncology products launched in India.
Zenotech's strategic collaboration with Sun Pharmaceutical Industries Limited has resulted in leasing its biotech API facility for R&D activities, reflecting a focus on innovation and growth.
Post its merger with Ranbaxy, Zenotech is under the influence of large promoters, including Daiichi Sankyo, positioning it advantageously in the pharmaceutical sector.
Pharmaceuticals
Pharmaceuticals - Indian - Formulations
275 Cr
Low Risk
96.0
43.4
3.3
2.9
73.49
44.11
Sales CAGR
1Y
9.14%
3Y
5.59%
5Y
10.59%
10Y
39.25%
Profit CAGR
1Y
28.74%
3Y
-36.74%
5Y
-12.23%
10Y
—
ROE
TTM
3.19%
3Y
9.48%
5Y
11.97%
10Y
0.80%
ROCE
TTM
9.08%
3Y
13.23%
5Y
11.28%
10Y
5.21%
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
325.00 | 389 Cr | — | 71.33 | 0.00 | -417.29 | -15.11 | -16.54 | |
148.00 | 350 Cr | 33.11 | 3.84 | 0.00 | 11.59 | 11.00 | 5.46 | |
45.13 | 275 Cr | 96.02 | 2.86 | 0.00 | 3.19 | 9.08 | 2.77 | |
216.00 | 268 Cr | 35.89 | 5.97 | 0.22 | 16.63 | 19.07 | 10.21 | |
433.00 | 245 Cr | 25.16 | 3.54 | 1.06 | 13.80 | 18.80 | 10.96 | |
153.55 | 242 Cr | 24.77 | 4.69 | 0.46 | 23.68 | 31.80 | 19.38 | |
48.05 | 169 Cr | — | 3.26 | 0.00 | -31.40 | -26.23 | -15.87 |
Performance
UNDER PERFORMER
Valuation
OVERVALUED
Growth
SLUGGISH
Profitability
MODERATE MARGIN
Technicals
Bearish
Risk
MODERATE RISK
